Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > Multiple factors tied to hearing loss in children treated with cisplatin

Multiple factors tied to hearing loss in children treated with cisplatin

Journal
The Lancet Child and Adolescent Health
    Reuters Health - 02/03/2021 - Although cumulative dose is important, how cisplatin is administered to young patients with cancer also appears to have a significant and additive effect on development of cisplatin-induced hearing loss (CIHL), according to a large multicenter study.

    "Cisplatin is a very effective chemotherapy agent but causes permanent hearing loss that is devastating to the children who survive their cancers," said Dr. Etan Orgel of Children's Hospital Los Angeles.

    "This study helps us understand how we might be able to make small changes in how we deliver the drug to cure the disease while also improving the child's quality of life for the decades that follow," he told Reuters Health by email.

    In a paper in The Lancet Child and Adolescent Health, Dr. Orgel and colleagues observe that most reports on the condition are limited by small numbers of patients, single-institution cohorts and inconsistencies leading to conflicting results.

    In an effort to avoid these problems the researchers examined data on 1,481 young patients treated with cisplatin at multiple cancer centers across Canada and the U.S. Of these patients, 1,275 were less than 15 years old and the remaining 206 were older; 96% had had audiometry done at their latest follow-up a mean of 3.9 years after diagnosis.

    Overall, 44%) developed moderate or severe CIHL, and the highest prevalence (59%) was seen in patients under 5. In addition, more than half of patients with CNS tumors, hepatoblastoma, and neuroblastoma had moderate or severe CIHL, but this was the case in less than a third of patients who received cisplatin for germ-cell tumors, osteosarcoma, or other cancers.

    After accounting for cumulative cisplatin dose, the team also found that higher fractionated doses were significantly associated with CIHL risk. For each 10mg/m2 increase per day, the adjusted odds ratio was 1.15. For each 50 mg/m2 increase per cycle, the corresponding aOR was 2.16.

    In addition, vincristine treatment was newly identified as a significant risk factor for CIHL (aOR, 3.55).

    The team found no difference in progression-free survival or overall survival between patients who developed moderate or severe CIHL at the end of therapy and those who did not.

    "Variations in cisplatin dosing confer additive risk for developing CIHL," they conclude, "and warrant investigation as a potential approach to decrease the burden of therapy."

    SOURCE: https://bit.ly/3qXKeqy The Lancet Child and Adolescent Health, online February 11, 2021.

    By David Douglas



    Posted on